BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 23466785)

  • 21. Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.
    Afshar-Oromieh A; Giesel FL; Linhart HG; Haberkorn U; Haufe S; Combs SE; Podlesek D; Eisenhut M; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1409-15. PubMed ID: 22669255
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
    AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA; Pampaloni MH; Nakakura E; VanBrocklin H; Slater J; Jivan S; Aparici CM; Yee J; Bergsland E
    Abdom Imaging; 2015 Aug; 40(6):1432-40. PubMed ID: 25820755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
    J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
    Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
    Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective comparison of
    Malaspina S; Anttinen M; Taimen P; Jambor I; Sandell M; Rinta-Kiikka I; Kajander S; Schildt J; Saukko E; Noponen T; Saunavaara J; Dean PB; Sequeiros RB; Aronen HJ; Kemppainen J; Seppänen M; Boström PJ; Ettala O
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2951-2959. PubMed ID: 33715033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
    Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
    Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].
    Pfannenberg C; Schwenzer N
    Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of metastases outside the liver and abdominal lymph nodes on
    Wedin M; Janson ET; Wallin G; Sundin A; Daskalakis K
    J Neuroendocrinol; 2024 May; 36(5):e13391. PubMed ID: 38590270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or
    Gariani J; Westerland O; Natas S; Verma H; Cook G; Goh V
    Crit Rev Oncol Hematol; 2018 Apr; 124():66-72. PubMed ID: 29548488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.
    Wulfert S; Kratochwil C; Choyke PL; Afshar-Oromieh A; Mier W; Kauczor HU; Schenk JP; Haberkorn U; Giesel FL
    Mol Imaging Biol; 2014 Aug; 16(4):586-94. PubMed ID: 24526358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
    Heusch P; Nensa F; Schaarschmidt B; Sivanesapillai R; Beiderwellen K; Gomez B; Köhler J; Reis H; Ruhlmann V; Buchbender C
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):42-8. PubMed ID: 25112399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
    Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
    Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
    BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
    Plathow C; Aschoff P; Lichy MP; Eschmann S; Hehr T; Brink I; Claussen CD; Pfannenberg C; Schlemmer HP
    Invest Radiol; 2008 May; 43(5):290-7. PubMed ID: 18424949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.